Homology Medicines Inc (NASDAQ:FIXX) COO Siyamak Rasty sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $20.00, for a total transaction of $160,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Siyamak Rasty also recently made the following trade(s):
- On Monday, June 3rd, Siyamak Rasty sold 8,000 shares of Homology Medicines stock. The stock was sold at an average price of $20.22, for a total transaction of $161,760.00.
NASDAQ:FIXX opened at $19.51 on Friday. The company has a market capitalization of $839.57 million, a PE ratio of -9.76 and a beta of 0.16. The firm has a fifty day moving average of $19.37. Homology Medicines Inc has a twelve month low of $15.07 and a twelve month high of $31.80.
Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in Homology Medicines by 137.1% in the fourth quarter. Rhumbline Advisers now owns 21,260 shares of the company’s stock worth $475,000 after purchasing an additional 12,294 shares in the last quarter. BlackRock Inc. raised its position in Homology Medicines by 134.3% in the fourth quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock worth $32,656,000 after purchasing an additional 837,099 shares in the last quarter. Bank of New York Mellon Corp raised its position in Homology Medicines by 114.0% in the fourth quarter. Bank of New York Mellon Corp now owns 58,527 shares of the company’s stock worth $1,308,000 after purchasing an additional 31,180 shares in the last quarter. Citigroup Inc. raised its position in Homology Medicines by 53.3% in the fourth quarter. Citigroup Inc. now owns 4,180 shares of the company’s stock worth $93,000 after purchasing an additional 1,453 shares in the last quarter. Finally, Northern Trust Corp raised its position in Homology Medicines by 49.6% in the fourth quarter. Northern Trust Corp now owns 181,361 shares of the company’s stock worth $4,055,000 after purchasing an additional 60,163 shares in the last quarter. Institutional investors and hedge funds own 52.87% of the company’s stock.
Several analysts recently weighed in on FIXX shares. Evercore ISI started coverage on shares of Homology Medicines in a report on Thursday, April 11th. They issued an “outperform” rating and a $29.00 price target on the stock. HC Wainwright set a $4.00 price target on shares of Uranium Energy and gave the company a “buy” rating in a report on Tuesday, June 11th. ValuEngine upgraded shares of Alleghany from a “hold” rating to a “buy” rating in a report on Friday, April 19th. Finally, Zacks Investment Research cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $29.10.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Read More: Gap Up Stocks
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.